Log in

NASDAQ:PRTAProthena Stock Price, Forecast & News

$10.98
+0.44 (+4.17 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.54
Now: $10.98
$11.22
50-Day Range
$9.67
MA: $10.71
$12.19
52-Week Range
$6.71
Now: $10.98
$17.63
Volume290,256 shs
Average Volume249,806 shs
Market Capitalization$438.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Read More
Prothena logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRTA
CUSIPN/A
Phone011-353-1236-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$810,000.00
Book Value$6.84 per share

Profitability

Net Income$-77,680,000.00
Net Margins-10,452.67%

Miscellaneous

Employees59
Market Cap$438.22 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Prothena (NASDAQ:PRTA) Frequently Asked Questions

How has Prothena's stock been impacted by COVID-19 (Coronavirus)?

Prothena's stock was trading at $9.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRTA shares have increased by 13.0% and is now trading at $10.98. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Prothena?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Prothena.

When is Prothena's next earnings date?

Prothena is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Prothena.

How were Prothena's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) announced its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.02. The biotechnology company had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.23 million. Prothena had a negative return on equity of 28.71% and a negative net margin of 10,452.67%. View Prothena's earnings history.

What price target have analysts set for PRTA?

4 brokerages have issued twelve-month price targets for Prothena's stock. Their forecasts range from $14.00 to $19.00. On average, they expect Prothena's stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 57.9% from the stock's current price. View analysts' price targets for Prothena.

Has Prothena been receiving favorable news coverage?

Media headlines about PRTA stock have trended somewhat negative on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Prothena earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Prothena.

Who are some of Prothena's key competitors?

What other stocks do shareholders of Prothena own?

Who are Prothena's key executives?

Prothena's management team includes the following people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)
  • Mr. Tran B. Nguyen, CFO & COO (Age 45)
  • Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)
  • Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 46)

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $10.98.

How big of a company is Prothena?

Prothena has a market capitalization of $438.22 million and generates $810,000.00 in revenue each year. The biotechnology company earns $-77,680,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Prothena employs 59 workers across the globe.

What is Prothena's official website?

The official website for Prothena is www.prothena.com.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.